DeciBio Consulting LLC has introduced a new Europe Oncology Genomics Tracker that sheds light on how genomic technologies are being assessed and integrated into solid tumor care across the five largest European markets, including France, Germany, Italy, Spain, and the United Kingdom. Built on feedback from more than one hundred medical oncologists, the report offers a detailed snapshot of how clinicians are approaching genomic testing in daily practice. It explores where adoption is accelerating, where barriers remain, and how priorities differ across healthcare systems in the region.
Health Technology Insights: Ambience Healthcare Teams With MultiCare on AI Platform Rollout
The tracker maps genomic testing across the full patient journey, from initial tumor profiling to minimal residual disease monitoring and treatment response assessment. Physicians were asked about their testing activity over the previous three months and their familiarity with diagnostic vendors operating in the space. The survey reached oncologists and hematologist oncologists who are actively treating patients and who have managed at least twenty five cases in the past quarter. Participation did not depend on whether respondents were currently using genomic testing, allowing the study to capture both users and non users for a balanced market perspective.
Health Technology Insights: Integrity Health Cuts Costs 16 Percentage Using Lightbeam Health Platform
Andrew Aijian, Partner at DeciBio Consulting LLC and lead author of the tracker, explained that understanding local dynamics is essential as precision medicine expands across Europe. He emphasized that each country operates within its own reimbursement structures and clinical infrastructure, which influences how quickly new genomic tools are adopted. According to Aijian, companies that want to succeed in precision oncology must understand these country specific nuances in order to identify opportunities, anticipate challenges, and tailor their strategies effectively.
Drawing on recent clinician responses, the report measures real world use of genomic tests for treatment selection and compares tissue and liquid biopsy approaches, panel sizes, and provider perceptions. It also examines the growing interest in circulating tumor DNA applications for monitoring recurrence and treatment response. By analyzing awareness levels, vendor positioning, and purchasing behavior, the tracker offers practical insights for biopharma companies, diagnostic developers, and investors seeking to navigate Europe’s evolving oncology landscape.
Although this marks the first edition focused on Europe, the tracker complements DeciBio’s established United States Oncology Genomics Tracker, which is published quarterly and follows similar metrics to monitor shifts in clinical practice over time.
Health Technology Insights: Lōkahi Therapeutics Welcomes UGA Fellows to ai² Futures Lab
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
